FDAnews
www.fdanews.com/articles/101193-thallion-reports-data-from-eco-4601-trial

Thallion Reports Data From ECO-4601 Trial

November 16, 2007

Canadian drugmaker Thallion Pharmaceuticals presented safety and efficacy data from a Phase I/II trial of ECO-4601 for the treatment of advanced cancer patients.

The trial was designed to examine the safety, pharmacologic profile and antitumor efficacy of ECO-4601 as a treatment in 26 advanced cancer patients.

The drug was administered in 21-day cycles consisting of a two-week continuous IV infusion followed by a one-week rest period.

The trial was conducted in two portions. The first portion was a dose-escalation study in 14 patients with doses ranging from 30–480 mg/m2. The second portion included 12 additional patients treated at the highest dose to obtain additional safety and pharmacokinetic data, Thallion said.